Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Webinars
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • AI and healthcare
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
      • Top Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • AI and healthcare
    • Industry Perspective
  • Home
  • News
  • Industry
  • Pharma News
  • Pharma Firm Secures...

Pharma Firm Secures Delhi HC Decree Over Z-CONTIN Mark

Written By : Susmita Roy Published On 2026-11-15T19:45:45+05:30  |  Updated On 16 Nov 2026 12:17 AM IST
Pharma Firm Secures Delhi HC Decree Over Z-CONTIN Mark
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email
New Delhi: The Delhi High Court has decreed a trademark infringement and passing-off suit in favour of Modi-Mundipharma against Arlak Biotech Private Limited and Kuresia Pharma over nitroglycerin-controlled release tablets marketed and manufactured under the mark "Z-CONTIN".

Granting summary judgment, Justice Vikas Mahajan held that continued use of the disputed mark could confuse the public about its association with Modi-Mundipharma’s registered “CONTIN” family of trademarks. The court awarded the pharmaceutical company Rs 2 lakh in nominal damages, in addition to costs, and disposed of the suit and pending applications.

The judgment, dated November 4, 2026, was delivered in Modi-Mundipharma Pvt. Ltd. v. Arlak Biotech Private Limited & Anr., CS(COMM) 1087/2025. The company had sought a permanent injunction against trademark and copyright infringement, dilution, tarnishment and passing off, along with rendition of accounts, damages and other reliefs. Its application for summary judgment was filed under Order XIII-A, read with Order VIII Rule 10 and Section 151 of the Code of Civil Procedure, 1908.

The dispute centred on the defendants’ use of “Z-CONTIN” for a pharmaceutical formulation that Modi-Mundipharma said was identical to its NITROCONTIN product. The plaintiff alleged that the defendants had adopted both the distinctive “CONTIN” component of its trademarks and a similar presentation for their nitroglycerin tablets, despite having no association with the company.

Explaining its rights, Modi-Mundipharma submitted that it was the registered proprietor of “NITROCONTIN” in Class 5 and held more than 80 registrations in that class for pharmaceutical products sharing “CONTIN” as a common feature. The registrations reproduced in the judgment included PHYLLOCONTIN, METOCONTIN, NITROCONTIN, UNICONTIN, CONTINUS and CONTIN. The table recorded the application for NITROCONTIN, Registration No. 518598, as dated October 19, 1989, and that for CONTIN, Registration No. 518594, as bearing the same date.

The company also relied on registration of NITROCONTIN in Hindi and registrations covering the trade dress of NITROCONTIN 2.6 and NITROCONTIN 6.4. It maintained that these registrations remained valid and subsisting. Beyond trademark protection, it claimed that the artwork, labels and trade dress associated with its CONTIN series, including NITROCONTIN, constituted original artistic works in which it was the first copyright owner under Section 17 of the Copyright Act, 1957.

Also Read:Delhi HC Grants Finecure Interim Relief Over Alleged Copying of Website, Business Credentials

Modi-Mundipharma further asserted that no third party held a Class 5 registration using “CONTIN” as a suffix. It argued that its family of marks, with “CONTIN” as the dominant component, had acquired substantial goodwill and reputation through longstanding sales and promotional activity.

To support that position, the company placed historical sales and advertising figures before the court. The tables reproduced in the judgment recorded domestic sales of CONTIN-series products at Rs 1,37,72,37,105 in 2024, with export sales of Rs 7,64,53,295. The separate NITROCONTIN sales table recorded sales of Rs 95,81,72,246 in 2024, compared with Rs 1,01,26,033 in 1995.

The plaintiff also relied on expenditure incurred in promoting its brands. For 2024, the figures reproduced in the judgment showed domestic advertising and promotional expenditure of Rs 3,72,36,929 for the CONTIN series and export-related expenditure of Rs 14,53,220. Advertising and promotional expenditure for NITROCONTIN in India was recorded at Rs 2,36,13,832 for the same year. These figures formed part of the company’s case that its marks had developed commercial recognition deserving protection.

Advocate Prachi Aggarwal, appearing for Modi-Mundipharma, submitted that the company had been vigilant in enforcing its rights and had secured several court orders restraining other parties from using infringing marks. She drew attention to the earlier proceedings identified in the plaint.

According to the plaintiff, Arlak Biotech operated through its division Soigner Pharma, which in turn had a further division, Cardiac Vintage, involved in marketing the disputed Z-CONTIN product. Kuresia Pharma was identified as its present manufacturer.

The company stated that it discovered the defendants’ nitroglycerin-controlled release tablets, 2.6 mg, being sold under “Z-CONTIN” in May 2025, both on IndiaMart and in physical stores across India. It relied on documentary material, including online listings and photographs of the competing products, to support its allegations.

On examining the product, Modi-Mundipharma said it found that the disputed mark was being used for the same formulation as its NITROCONTIN 2.6 mg tablets. It also pointed to the description “controlled release tablets”, used on the competing product, and referred to its own NITROCONTIN products in strengths of 2.6 mg and 6.4 mg.

The plaintiff alleged that Arlak’s adoption was dishonest, pointing particularly to the similar pink-and-white colour combination used for its 2.6 mg product. The judgment reproduced photographs of the parties’ packaging, including the NITROCONTIN bottles and Z-CONTIN bottles marketed under the Cardiac Vintage name.

Before approaching the court, Modi-Mundipharma issued a cease-and-desist notice dated May 19, 2025, to Arlak Biotech and the product’s then manufacturer, Gnosis Pharmaceuticals Pvt. Ltd. According to the plaintiff’s account recorded in the judgment, Arlak did not respond.

Gnosis, however, replied on June 19, 2025, undertaking to stop manufacturing the product under “Z-CONTIN” or any mark deceptively similar to the CONTIN series. In view of that undertaking, Modi-Mundipharma did not implead Gnosis as a defendant in the present suit.

The plaintiff separately alleged that Kuresia Pharma, the current manufacturer, was a habitual infringer. In support, it referred to another pending suit, Modi Mundipharma v. Care Formulation Labs Pvt. Ltd. and Anr., CS(COMM) 444/2025. It stated that an order dated May 14, 2025, in that matter had restrained the defendants there, including Kuresia, from manufacturing, selling, offering for sale, advertising or otherwise dealing in products bearing the registered CONTIN mark or an identical or deceptively similar mark. The description of Kuresia as a habitual infringer was the plaintiff’s allegation.

The defendants did not put forward a defence in the present proceedings. The court recorded that, despite being duly served, they had not entered appearance. Their right to file written statements was closed on April 10, 2026, and they were proceeded against ex parte on August 12, 2026. The judgment therefore contains no substantive explanation from Arlak or Kuresia for adopting Z-CONTIN, no challenge from them to the plaintiff’s registrations, and no defence concerning the alleged packaging similarities.

Relying on that procedural position, Modi-Mundipharma’s counsel argued that the allegations in the plaint remained uncontroverted. She pressed for relief under prayer 62(i) to (v) of the plaint and stated that, on the monetary claim, the company would seek nominal damages and costs.

In support of summary disposal, counsel cited DS Confectionary Products Limited v. Nirmala Gupta and Anr., 2022 SCC OnLine Del 4013. The court discussed that decision, in which summary judgment had been granted against defendants who had neither filed written statements nor appeared to defend the proceedings, with damages of Rs 2 lakh also awarded.

The judgment reproduced the discussion in that precedent concerning Su-Kam Power Systems Ltd. v. Kunwer Sachdev, 2019 SCC OnLine Del 10764. That discussion explained that summary judgment in commercial disputes is available where a defendant has no real prospect of successfully defending the claim and there is no compelling reason to require oral evidence. It distinguished realistic prospects of success from merely fanciful ones and recognised that a full trial need not be the default procedure in every commercial dispute.

Justice Mahajan also referred to Disney Enterprises I.N.C. & Anr. v. Balraj Muttneja & Ors., 2014 SCC OnLine Del 781. The passage reproduced from that decision explained that, where defendants are ex parte and the available material sufficiently supports the plaintiff’s claim, requiring further ex parte evidence may merely repeat the plaint and unnecessarily prolong the proceedings.

After hearing Modi-Mundipharma’s counsel and examining the record, the court recognised the company’s registered CONTIN mark and series of trademarks. It found that allowing the defendants to continue using the disputed mark could create confusion among the general public about an association between the competing marks.

The court stated:

“In view thereof, allowing the defendants to continue with the impugned mark can lead to a likelihood of confusion in the minds of general public as regards to the association of the defendants’ marks with that of the plaintiff. Therefore, the plaintiff is entitled to protection under the Act against infringement as well as passing off.”

The court further noted that the defendants had not appeared, their opportunity to file written statements had already been closed, and the proceedings against them were ex parte. Consequently, the averments in the plaint remained uncontroverted.

Also Read:Sun Pharma's HISTAC, OMESEC Trademark Settlement Approved by Bombay HC

Applying the reasoning in DS Confectionary and Disney, Justice Mahajan held that Modi-Mundipharma was entitled to summary judgment under Order XIII-A of the CPC, as applicable to commercial disputes, read with Rule 27 of the IPD Rules.

The final operative directions, reproduced exactly from paragraphs 26 to 29 of the judgment, were:

"26. The suit is, therefore, decreed in terms of prayer 62 (i) to (v).

  1. The plaintiff is also awarded decree of nominal damages of Rs. 2,00,000/-, in addition to costs.

  2. Let decree be drawn in the above terms.

  3. The suit, along with pending applications, is disposed of.”

To view the official order, click the link below:

https://medicaldialogues.in/pdf_upload/2026/11/15/modi-mundipharma-711365-483718.pdf

modimundipharmaarlak biotechkuresia pharmazcontinnitrocontincontintrademarktrademark infringementnitroglycerindelhi hcdelhi high court

Medical Survey

Susmita Roy
Susmita Roy

    Mpharm (Pharmacology)

    Susmita Roy, B pharm, M pharm Pharmacology, graduated from Gurunanak Institute of Pharmaceutical Science and Technology with a bachelor's degree in Pharmacy. She is currently working as an assistant professor at Haldia Institute of Pharmacy in West Bengal. She has been part of Medical Dialogues since March 2021.

    Print Article
    Show Full Article
    Next Story
    Recommended For You
    NO DATA FOUND

    Editorial

    Jural Exploitation of Healthcare Professionals and Institutions in the PM-RAHAT Scheme - Dr Rajeev Joshi

    Jural Exploitation of Healthcare Professionals and Institutions in the PM-RAHAT Scheme - Dr Rajeev...

    Metformin - Eight Points on a Metabolic Anchor in T2D: World Diabetes Day Special

    Metformin - Eight Points on a Metabolic Anchor in T2D: World Diabetes Day Special

    Clinical Insights for Allergic Rhinitis Management with Fexofenadine and Pseudoephedrine Combination - Dr. Makarand Damle

    Clinical Insights for Allergic Rhinitis Management with Fexofenadine and Pseudoephedrine Combination...

    Effect of Saroglitazar in MASLD: Latest Indian 2026 Study

    Effect of Saroglitazar in MASLD: Latest Indian 2026 Study

    Beyond the Lipid Panel: Elevated Lp(a), Lifetime Risk and What the Evidence Says About Aspirin- Dr Ambar Bhatnagar

    Beyond the Lipid Panel: Elevated Lp(a), Lifetime Risk and What the Evidence Says About Aspirin- Dr...

    View All

    Journal Club Today

    Clinical Insights for Allergic Rhinitis Management with Fexofenadine and Pseudoephedrine Combination - Dr. Makarand Damle

    Clinical Insights for Allergic Rhinitis Management with Fexofenadine and Pseudoephedrine Combination...

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok